Can adding a fourth drug shrink large liver tumors that invade the portal vein?
NCT ID NCT06904183
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 participants will be randomly assigned to receive either the three-part or four-part treatment. The main goal is to see how long it takes for the cancer to progress, with secondary goals including response rates and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of lenvatinib (a targeted therapy), sintilimab (an immunotherapy), drug-eluting bead transarterial chemoembolization (DEB-TACE), and hepatic arterial infusion chemotherapy (HAIC) with FOLFOX regimen.
- What this could lead to
- If adding HAIC improves outcomes, it could offer a more effective treatment option for people with large liver cancers that have spread into the portal vein.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The added chemotherapy may increase side effects without improving overall survival, and the benefit may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510260, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new imaging agent could tell doctors which liver cancers will resist immunotherapy
- Can a Four-Drug cocktail tame inoperable liver cancer?
- Chemo-loaded microspheres aim to starve liver tumors from within
- New combo therapy aims to stop liver cancer in its tracks
- New combo therapy aims to shrink liver tumors in Hard-to-Treat patients
- New combo shrinks untouchable liver tumors, opens door to surgery